Reata Pharmaceuticals Inc (NASDAQ:RETA) Receives Consensus Recommendation of “Buy” from Analysts
Shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) have earned an average recommendation of “Buy” from the eleven research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $273.57.
RETA has been the topic of several research reports. National Securities downgraded Reata Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th. Stifel Nicolaus reissued a “buy” rating and set a $305.00 price targ ...